The problematic HTA Review options paper should trigger a discussion of how agreements with the federal government have moved so far from their original intent of rewarding the industry's acceptance of pricing reforms to become platforms for policymakers to accelerate their own ambitions for change.
Agreements that started with limits have become vehicles for government-initiated change
March 1, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
OncoSil completes first production run at new Sydney manufacturing facility
December 17, 2025 - - Australian Biotech -
Island Pharmaceuticals secures key partnership with Texas Biomed
December 17, 2025 - - Australian Biotech -
Novartis names new Country President following leadership transition
December 16, 2025 - - Latest News -
Mayne Pharma opens expanded manufacturing facility after termination of takeover
December 16, 2025 - - Latest News -
Budget update includes impact of listings, but generally not much else
December 16, 2025 - - Latest News -
The UK reconfirms the direct impact of the transatlantic shift in medicine pricing
December 16, 2025 - - Latest News -
The industry is probably right to resist, it just needs to prepare for the response
December 16, 2025 - - Latest News
